Browse studies

Find your next paid study

26,882 recruiting studies available now

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess th…

A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies

This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that ha…

Colorectal CancerNon-Small Cell Lung CancerBreast Cancer+3 more

Estimated

~$10 – $8,750

Immunome, Inc.NCT07578571

Observational

Identifying Residual Connectivity in Veterans With Spinal Cord Injury for Precision Neurorehabilitation

Chronic spinal cord injury (SCI) is a debilitating disorder in Veterans and the broader U.S. population that does not have a cure. Veterans with severe SCI dem…

Spinal Cord Injuries

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT07222046

Observational

Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptoma…

Aortic Stenosis, Severe

Estimated

~$10 – $7,500

Edwards LifesciencesNCT05172960

A Repository to Study Host-Microbiome Interactions in Health and Disease

Background: The microbiome is the bacteria and other microorganisms that live inside and on the body. The microbiome is important for our health. Researchers …

Healthy ControlsPregnancyPediatric Illnesses+1 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT05656378

Phase 1

A Phase 1/2, First-in-human, Double-blind, Placebo-controlled Study to Assess Dose, Safety, and Efficacy of UX016 (Sialic Acid-C16 Prodrug) in Adults With GNE Myopathy

The goal of this study is to assess the safety and dose of UX016 and its impact on muscle strength in adults with GNE Myopathy (GNEM).

GNE Myopathy

Estimated

~$10 – $8,750

Ultragenyx Pharmaceutical IncNCT07511556

Phase 2

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to…

Advanced Solid TumorsHER2 Mutation

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based p…

Solid TumorsHematologic Malignancies

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT03486873

Observational

Building Teachers Mental Health Skills to Support Students With Mental Health Needs in Elementary and Middle Schools in North Carolina: Program Implementation and Prospective Data Collection

Purpose: The purpose of this research is to pilot test a novel, alternative, potentially sustainable system of teacher-delivered, task-shifted child mental hea…

Child BehaviorMental Health IssuePsychosocial Functioning+2 more

Estimated

~$10 – $6,250

University of North Carolina, Chapel HillNCT06587230

Phase 1

Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol

VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial…

Heterozygous Familial HypercholesterolemiaPremature Coronary Heart Disease

Estimated

~$10 – $8,750

Verve Therapeutics, Inc.NCT06164730

Phase 1

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in comb…

Non-small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNSCLC+3 more

Estimated

~$10 – $8,750

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06343402

Phase 2

Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen…

Core Binding Factor Acute Myeloid Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06917911